CDMO Trends 2026: What’s Driving Mergers And Acquisitions

Introduction

If you've been anywhere near the pharmaceutical world lately, you've probably noticed a pattern: contract development and manufacturing organizations, better known as CDMOs, keep buying each other, buying pharma facilities, or getting themselves bought. It's not a coincidence and it's not a phase. It's a genuine consolidation wave, and it's reshaping how medicines actually get made.

Let's slow down and unpack what's happening, why it's happening now, and what it means for the industry going forward — in plain, simple terms.

What Exactly Is A CDMO, Quickly?

A CDMO is basically a company that other pharma and biotech companies hire to help develop and manufacture their drugs. Instead of every biotech building its own factory, it can outsource that work to a CDMO that already has the equipment, expertise, and regulatory know-how. It's efficient, flexible, and has become the backbone of how modern medicines reach patients.

Now, onto the consolidation part.

The Deals Are Getting Bigger, And More Frequent

The clearest sign of this wave is the sheer scale of recent transactions. One of the biggest examples is Novo Holdings' $16.5 billion purchase of Catalent, a deal that signaled a decisive shift toward end-to-end providers that combine development, scale-up, and commercial production in one place.

But it's not just the mega-deals. Smaller, quieter transactions are piling up too:

• Samsung Biologics, Rois, and Adragos Pharma each completed pharma-facility acquisitions within just a two-day window in early spring 2026, a burst of activity that followed a slower stretch of deals in prior months.

• Private equity firms GHO and Ampersand acquired Avid Bioservices for roughly $1.1 billion, and GI Partners picked up Charles River Laboratories' advanced therapies manufacturing business, reflecting how deeply private equity remains woven into CDMO growth and strategy.

• Celltrion completed its purchase of Eli Lilly's API manufacturing site in New Jersey, and later committed hundreds of millions more to expand it.

Dealmakers describe this as a genuine rebound after a slower period. One senior dealmaker put it simply: the industry entered 2026 with roughly twice the deal value and volume compared to the same point in 2025 and 2025 was already a growth year.

CDMO consolidation is just one piece of a much bigger pharma M&A wave in 2026. See the full list of the year's biggest deals across the industry.
→ Read: Top Pharma Mergers in 2026: Key Deals Explored

Why Is This Happening Right Now?

There isn't just one reason behind the wave — it's a mix of forces all pushing in the same direction at the same time.

1) Onshoring Pressure — Governments and pharma companies alike want more domestic manufacturing for national security and supply-chain reasons, and regulatory moves such as the BIOSECURE Act are expected to reward companies that keep production local.

2) Tariff Uncertainty — Shifting trade policy is pushing drugmakers to retool their manufacturing networks and sell off facilities to CDMOs that can operate them more efficiently, as pharmaceutical companies retool their manufacturing needs amid industry-wide moves to onshore US production.

3) Improving Financing Conditions — After a rough patch between 2022 and 2024, when rising interest rates hit biopharma valuations hard, credit markets are recovering, giving buyers more room to act before prices climb again.

4) A Shift Toward Specialization — The last big M&A cycle, which peaked around 2021, was about CDMOs trying to do everything for everyone. That approach is fading. The next phase is about going deep rather than wide.

From "Do Everything" To "Do It Better"

This is probably the most important shift happening beneath the surface of all these deals. A decade ago, many CDMOs raced to expand into as many service areas as possible. Today, the smarter strategy is narrower and sharper.

Companies are now consolidating around specific high-value capabilities such as:

• Sterile injectables

• Radiopharmaceuticals

• Complex biologics and monoclonal antibodies

• Antibody-drug conjugates, an area where over 300 candidates were in clinical development as of 2025, making capacity in this space extremely valuable and hard to come by

• Cell and gene therapy manufacturing
  

Some companies are acquiring smaller specialists to build this expertise. Others are shedding non-core assets to focus on what they do best. Either way, the direction is the same: fewer generalists, more specialists.

Specialization is reshaping who wins in contract manufacturing. Here's the full map of the top CDMOs leading that shift in 2026.
→ Read: Pharmaceutical Contract Manufacturing Market 2026: Top CDMOs, Growth Trends & Strategic Shifts

The Numbers Behind The Trend

It helps to see the scale of what we're actually talking about here:

• The global CDMO market was valued at roughly $197 billion in 2025 and is projected to grow to around $211 billion in 2026, eventually reaching close to $393 billion by 2035.

• A separate industry estimate places the global CDMO sector at around $275 billion in 2026, forecasting growth to $375 billion by 2031.

• Broader biopharma dealmaking has also picked up, with bio/pharma M&A totaling $40.9 billion across 32 deals in the first quarter of 2026 alone.

The exact figures differ depending on which research firm you ask, but the pattern across all of them tells the same story: this is a sector growing quickly, and consolidation is one of the main engines driving that growth.

Who Benefits, And Who Feels The Squeeze?

Consolidation never affects everyone the same way. Here's a simple breakdown of how different players are experiencing this wave.

Likely To Benefit:

1. Large, well-capitalized CDMOs that can absorb acquisitions and offer end-to-end services from early development through commercial-scale production.

2. Pharma companies retooling their manufacturing networks, who now have more CDMO buyers willing to purchase entire facilities rather than leaving them idle.

3. Investors, particularly private equity firms, who continue to see CDMOs as a reliable long-term growth story.

Facing Real Pressure:

1. Smaller, generalist CDMOs that lack a clear specialty may struggle to compete or attract buyers, since the current cycle favors narrower expertise over broad service offerings.

2. Early-stage and clinical-phase CDMOs, which are seeing a more muted demand profile as biotech funding remains uneven.

3. Medical-device CDMOs facing a possible reversal, as some original equipment manufacturers reconsider bringing certain services back in-house due to cost and reimbursement pressures.

What Does This Mean Going Forward?

For biotech companies choosing a manufacturing partner, this wave changes the calculus. A CDMO that looked stable and well-positioned two years ago might be an entirely different organization today, under new ownership, with a different strategic focus. That makes due diligence more important than ever before signing a long-term manufacturing agreement.

For the industry as a whole, consolidation isn't inherently good or bad. It can bring real benefits, like stronger capacity, better technology investment, and more integrated services from development through commercial supply. But it can also concentrate risk, since fewer, larger players mean a single company's setback can ripple more widely across the supply chain.

In Conclusion 

The CDMO consolidation wave isn't a passing trend, it's a structural shift in how the pharmaceutical manufacturing world is organizing itself. Bigger deals, sharper specialization, and stronger onshoring pressure are all pushing the industry toward fewer, more capable, more focused players. 

For pharma companies, investors, and patients alike, the outcome of this wave will shape not just who manufactures tomorrow's medicines, but how reliably, safely, and affordably those medicines actually reach the people who need them.

The consolidation may be happening in boardrooms and deal rooms, but its real impact will eventually show up somewhere far more important: on pharmacy shelves and in hospital treatment rooms around the world.

FAQs

1. Why Are CDMOs Merging And Acquiring Other Companies?

CDMOs are consolidating to expand their manufacturing capabilities, gain specialized expertise, increase production capacity, and offer more end-to-end services. Onshoring pressure, changing trade policies, improving financing conditions, and growing demand for specialized manufacturing are also driving M&A activity.

2. How Is CDMO Consolidation Changing The Pharmaceutical Industry?

Consolidation is creating larger and more specialized CDMOs that can support drug development and manufacturing at a broader scale. While this can improve capacity, technology investment, and supply-chain efficiency, it may also increase dependence on fewer major manufacturing providers.

3. What Does CDMO Consolidation Mean For Pharma And Biotech Companies?

Pharma and biotech companies may have access to more advanced capabilities and integrated manufacturing services, but they also need to carefully evaluate potential partners. Changes in ownership, strategic priorities, capabilities, and capacity following an acquisition can affect long-term manufacturing agreements and supply security.